CMS grants transitional drug add-on payment adjustment to Korsuva injection
Click Here to Manage Email Alerts
Cara Therapeutics Inc. announced that Korsuva injection received CMS transitional drug add-on payment adjustment in the anti-pruritic functional category.
The transitional drug add-on payment adjustment (TDAPA) will apply to Korsuva (difelikefalin) injection from April 4, 2022, to April 4, 2024. According to the press release, Korsuva is the second product to be approved for TDAPA, which allows payments for new injectable end-stage kidney disease therapies to be reimbursed outside of the ESRD Prospective Payment System bundle.
"Receiving TDAPA from CMS is a crucial step toward the commercial launch of Korsuva injection, which we believe will benefit thousands of chronic kidney disease patients undergoing dialysis who suffer from pruritus," Christopher Posner, president and CEO of Cara Therapeutics, said in the release. "We are pleased to have secured TDAPA reimbursement for Korsuva injection and are encouraged by the willingness of CMS leadership to engage with Cara and Vifor Pharma regarding potential post-TDAPA support."
In August 2021, Cara Therapeutics and Vifor Pharma, the commercial partner for Korsuva, announced that Korsuva injection was approved by the FDA for treating pruritus associated with CKD in patients undergoing hemodialysis.
"We are pleased to have secured TDAPA reimbursement in the United States for Korsuva injection effective April 2022, and we look forward to bringing this important treatment option to the people who need it," Molly Painter, U.S. president of Vifor Pharma, said in the release.
Click Here to Manage Email Alerts